

May 29, 2026

To

BSE Limited  
Corporate Relationship Department  
25th Floor, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001.  
**BSE Scrip Code: 524743**

National Stock Exchange of India Ltd.  
Exchange Plaza, 5th floor  
Plot No. C/ 1, G Block,  
Bandra-Kurla Complex Bandra (E),  
Mumbai - 400 051.  
**NSE Symbol: FISCHER**

Dear Sir/ Madam,

**Sub: Outcome of Board Meeting held on 29<sup>th</sup> May, 2026**

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (29/05/2026):

**1. Financial Results**

Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended 31/03/2026, Statement of Assets & Liabilities and Statement of Cash Flow for the year ended on March 31<sup>st</sup> 2026 along with Auditors Report (Standalone and Consolidated) thereon and Declaration in respect of Audit Report (Standalone and Consolidated) with unmodified opinion under Regulation 33(3)(d) of the Listing Regulations are enclosed herewith as **Annexure-1**.

We hereby confirm and declare that the Statutory Auditors of the Company i.e., M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai, have issued their audit report on Standalone and Consolidated Financial Statements of the Company for the year ended 31st March 2026 with an unmodified opinion.

**2. Appointment of Internal Auditors:**

On the recommendation of Audit Committee, the Board of Directors in their meeting held today has approved the appointment of the Internal Auditors, S. Ramanand Aiyer & Co., Chartered Accountants, for the Financial Year 2026-27, details of the appointment are enclosed as **Annexure -2**.

### **3. Dividend**

The Board has recommended to the members of the Company for a final dividend of Rs. 0.05/- per equity share for the financial year ended 31st March 2026, which shall be paid/ dispatched within 30 days from the date of ensuing Annual General Meeting ('AGM'), on approval by the members at the AGM.

The date of the ensuing Annual General Meeting will be intimated to the Stock Exchanges in due course of time.

The Board Meeting commenced at 9.00 PM (IST) and concluded at 11.00 PM (IST).

Please take on record.

Thanking You,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**



**BALAJI GANDLA**

**COMPANY SECRETARY AND COMPLIANCE OFFICER**

FISCHER MEDICAL VENTURES LIMITED  
CIN: L86900AP1993PLC118162

Regd Off: No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Visakhapatnam, Andhra Pradesh, India, 530044  
Corp off: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006, India  
Email: cs@fischermv.com | Website: www.fischermv.com

**Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended 31.03.2026 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.**

Rs. In Lakhs											
SL NO	PARTICULARS	STANDALONE					CONSOLIDATED				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue From Operations	410.76	131.50	521.97	1,739.18	521.97	9,773.04	10,109.52	4,917.42	30,857.56	11,069.87
II	Other Income	43.40	85.67	64.93	349.34	345.70	127.78	108.81	14.87	1,231.37	149.20
III	Total Income (I + II)	454.16	217.17	586.90	2,088.52	867.67	9,900.83	10,218.33	4,932.29	32,088.93	11,219.07
IV	Expenses										
	Cost Of Materials Consumed	-	-	-	-	-	6,209.35	-	-	6,224.23	-
	Purchase of Traded Assets	276.83	136.79	454.56	1,195.68	461.06	690.33	5,781.06	3,472.30	8,349.15	9,528.18
	Changes in inventories of finished goods, by-products and work in progress	4.58	(40.03)	-	(35.45)	(6.50)	(53.55)	(891.88)	458.75	(315.59)	(369.22)
	Employee Benefits Expense	52.39	61.81	4.74	201.51	12.84	402.13	416.77	93.58	1,509.42	258.13
	Direct Expense	-	-	-	-	-	256.43	127.36	-	5,301.23	-
	Depreciation and Amortisation Expenses	43.39	8.16	9.86	67.86	12.72	92.57	77.01	51.03	297.93	163.28
	Finance Costs	126.55	95.89	12.41	465.23	13.17	360.83	63.71	22.63	583.40	46.68
	Other Expenses	967.10	104.71	218.48	1,244.27	278.30	2,168.05	2,519.71	642.46	5,480.78	1,321.11
	Total Expenses	1,470.84	367.34	700.05	3,139.11	771.59	10,126.12	8,093.74	4,740.75	27,430.55	10,948.16
V	Profit / (Loss) Before Exceptional Items & Tax (III - IV)	(1,016.68)	(150.16)	(113.15)	(1,050.58)	96.08	(225.30)	2,124.59	191.54	4,658.38	270.92
VI	Share of profit/(loss) of Associates	-	-	-	-	-	1.08	(5.74)	(10.32)	(22.19)	(48.65)
VI	Exceptional Items	-	-	-	-	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	(1,016.68)	(150.16)	(113.15)	(1,050.58)	96.08	(224.22)	2,118.85	181.22	4,636.19	222.27
VIII	Tax Expense										
	Current Tax	(9.00)	-	(3.40)	(9.00)	(57.40)	(842.87)	(172.25)	(59.35)	(1,731.88)	(113.35)
	Deferred Tax (Asset) / Liability	127.50	(16.77)	27.50	17.29	27.64	357.32	(23.12)	9.35	197.63	11.87
IX	Profit / (Loss) For The Period From Continuing Operations (VII - VIII)	(898.19)	(166.93)	(89.05)	(1,042.29)	66.32	(709.78)	1,923.48	131.22	3,101.94	120.79
X	Profit / (Loss) From Discontinued Operations	-	-	-	-	-	-	-	-	-	-
XI	Tax Expense Of Discontinued Operations	-	-	-	-	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinued Operations After Tax (X - XI)	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) For The Period (IX + XII)	(898.19)	(166.93)	(89.05)	(1,042.29)	66.32	(709.78)	1,923.48	131.22	3,101.94	120.79
XIV	Items That Will Not Be Reclassified To Profit / (Loss)										
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	-	-	-	-	-	-	-	(0.78)	(5.43)	(0.78)
	(ii) Income Tax Relating On Above	-	-	-	-	-	-	-	-	-	-
	(iii) Equity Instruments Through Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income - Total	-	-	-	-	-	-	-	-	(5.43)	-
XV	Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))	(898.19)	(166.93)	(89.05)	(1,042.29)	66.32	(709.78)	1,923.48	130.44	3,096.51	120.01
XVI	Paid Up Equity Share Capital (Face Value Re.1/-)	6,545.15	6,485.15	6,380.15	6,545.15	6,380.15	6,545.15	6,485.15	6,380.15	6,545.15	6,380.15
XVII	Other Equity	-	-	-	-	24,166.26	-	-	-	-	24,350.14
XVIII	Earnings Per Share (EPS) From Continuing Operations & Discontinued Operations (In Rs.)										
	Basic	(0.14)	(0.03)	(0.01)	(0.16)	0.01	(0.11)	0.30	0.01	0.48	0.02
	Diluted	(0.13)	(0.03)	(0.01)	(0.15)	0.00	(0.10)	0.29	0.01	0.45	0.02

// BY ORDER OF THE BOARD //

For and on behalf of the Board  
Fischer Medical Ventures Limited



Chairman & Managing Director  
DIN : 03137661

Date: 29.05.2026

May 29, 2026

**Declaration under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

I, RAVINDRAN GOVINDAN, Chairman & Managing Director of FISCHER MEDICAL VENTURES LIMITED (CIN: L86900AP1993PLC118162) having its Registered Office at Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032, hereby declare that the Statutory Auditor M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai, Chennai (FRN: 101490W) have issued an Audit Report (Standalone and Consolidated) with unmodified opinion on Audited Financial Results of the Company for the Quarter and Financial Year ended 31/03/2026.

This declaration is given in compliance to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your record.

Thanking You,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**



**RAVINDRAN GOVINDAN**  
**CHAIRMAN & MANAGING DIRECTOR**

**Independent Auditor's Report on Standalone Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)**

**Opinion**

1. We have audited the accompanying statement of Standalone Audited Annual Financial Results ('the Statement') of **Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)** for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
  - (i) Is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, and
  - (ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company year ended 31 March 2026.

**Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under Section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion

### **Responsibilities of Management and Those Charged with Governance for the Statement**

4. This Statement has been prepared on the basis of the standalone annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit or loss and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Statement**

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under Section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.


- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
  - Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.
  - Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
  - Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.
9. Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.
10. We communicate with those charged with governance regarding among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.
11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

12. The Statement includes the financial results for the quarter ended 31 March 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

Our opinion is not modified in respect of above matters.

For Bilimoria Mehta & Co  
Chartered Accountants  
Firm Registration No.: 101490W





**Aakash Mehta**  
**Partner**

Membership No: 165824  
UDIN: 26165824RLUKDO2883  
Place of Signature: Mumbai  
Date: May 29, 2026

## Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900AP1993PLC118162

Standalone Balance Sheet as at March 31st, 2026

(Amount in lakhs)

Particulars	As At 31 March 2026	As At 31 March 2025
<b>Assets</b>		
<b>(1) Non-Current Assets</b>		
(a) Property, plant and equipment	2.91	0.38
(a) Non-current tax assets		
(c) Other non-current assets		
ROU Asset	1,133.33	67.55
Deferred Tax Asset (Net)	-	27.63
Other Non Current Assets	53.29	62.30
<b>Financial Assets</b>		
(i) Investments	30,354.97	29,053.31
(ii) Other Financial asset	4,317.80	3,884.54
<b>Total Non-Current Assets</b>	<b>35,862.30</b>	<b>33,095.69</b>
<b>(2) Current assets</b>		
(a) Inventories	41.95	6.50
(b) Financial assets		
(i) Trade receivables	2,071.01	1,707.68
(ii) Cash and cash equivalents	113.85	28.71
(iii) Other Current Financial Asset	203.83	357.80
(b) Other Current Asset		
-Loans and Advances		
-Other Current Financial Asset	-	
(c) Current Tax Asset (Net)	9.15	
(d) Other Current Assets	518.13	654.05
<b>Total Current Assets</b>	<b>2,957.92</b>	<b>2,754.74</b>
<b>Total Assets</b>	<b>38,820.22</b>	<b>35,850.44</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	6,545.15	6,380.15
(b) Other Equity		
Reserve & Surplus	24,684.13	24,166.26
(c) Money Received Against Share Warrants	2,583.95	3,022.10
<b>Total Equity</b>	<b>33,813.23</b>	<b>33,568.51</b>
<b>Liabilities</b>		
<b>(1) Non-Current Liabilities</b>		
(a) Deferred Tax Liability	(44.92)	
(b) Financial Liabilities		
(i) Lease Liabilities	2,559.81	1,569.71
(ii) Borrowings	1,296.96	
(iii) Other Non Current Liabilities		
(iv) Provisions	10.40	
<b>Total Non-Current Liabilities</b>	<b>3,822.25</b>	<b>1,569.71</b>
<b>(2) Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings		
(i) Lease Liabilities	708.00	637.88
(ii) Trade payables		
total outstanding dues of micro enterprises and small enterprises	219.60	2.05
total outstanding dues of creditors other than micro enterprises and small enterprises	144.82	37.36
(iii) Other Financial liabilities	69.52	4.92
(b) Short Term Provisions	13.08	
(b) Other Current Liabilities	29.71	8.90
(c) Current Tax Liability (Net)		21.11
<b>Total Current Liabilities</b>	<b>1,184.73</b>	<b>712.22</b>
<b>Total Equity and Liabilities</b>	<b>38,820.22</b>	<b>35,850.44</b>

**Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)**  
**CIN : L86900AP1993PLC118162**  
**Statement of Unaudited Financial Results for the Quarter and Year Ended March 31, 2026**

(Amount in lakhs)

Particulars	Quarter Ended			Year ended	
	31st March 2026	31st December 2025	31st March 2025	31st March 2026	31st March 2025
	Audited	Unaudited	Audited	Audited	Audited
I) <b>Revenue From Operations</b>	410.76	131.50	521.97	1,739.18	521.97
II) <b>Other Income</b>	43.40	85.67	64.94	349.34	345.70
III) <b>Total Income (I+II)</b>	<b>454.16</b>	<b>217.17</b>	<b>586.90</b>	<b>2,088.52</b>	<b>867.67</b>
IV) <b>Expenses :</b>					
Cost of Materials Consumed	-	-	-	-	-
Purchase of Traded Goods	276.83	136.79	454.56	1,195.68	461.06
Changes in inventories of finished goods, by-products and work in progress	4.58	(40.03)	-	(35.45)	(6.50)
Employee Benefit expenses	52.39	61.81	4.74	201.51	12.84
Depreciation and Amortization Expenses	43.39	8.16	9.86	67.86	12.72
Finance Cost	126.55	95.89	12.41	465.23	13.17
Other Expenses	967.10	104.71	218.48	1,244.27	278.30
<b>Total Expenses (IV)</b>	<b>1,470.84</b>	<b>367.34</b>	<b>700.05</b>	<b>3,139.11</b>	<b>771.58</b>
V) <b>Profit (Loss) Before exceptional and tax (III-IV)</b>	<b>(1,016.68)</b>	<b>(150.16)</b>	<b>(113.15)</b>	<b>(1,050.58)</b>	<b>96.08</b>
VI) Exceptional Items	-	-	-	-	-
VII) <b>Profit before tax (V-VI)</b>	<b>(1,016.68)</b>	<b>(150.16)</b>	<b>(113.15)</b>	<b>(1,050.58)</b>	<b>96.08</b>
VIII) <u>Tax Expenses</u>					
i) Current Tax	(9.00)	-	2.00	(9.00)	(52.00)
ii) Deferred Tax	127.50	(16.77)	27.50	17.29	27.64
iii) Tax pertaining to previous year	-	-	(5.40)	-	(5.40)
IX) <b>Profit (Loss) from Continuing Operations (VII-VIII)</b>	<b>(898.19)</b>	<b>(166.93)</b>	<b>(89.05)</b>	<b>(1,042.29)</b>	<b>66.32</b>
X) <b>Other Comprehensive income;</b>					
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XI) <b>Total Comprehensive Income for the period (Comprising profit/(loss) and other Comprehensive Income for the period (IX-X))</b>	<b>(898.19)</b>	<b>(166.93)</b>	<b>(89.05)</b>	<b>(1,042.29)</b>	<b>66.32</b>
XII) <b>Paid up Equity Share Capital (Face Value Re.1/-)</b>	6,485.15	6,485.15	5,350.00	6,481.15	5,350.00
XIII) <u>Earnings per Equity Shares</u>					
1) Basic	<b>(0.14)</b>	<b>(0.03)</b>	<b>(0.06)</b>	<b>(0.16)</b>	<b>0.05</b>
2) Diluted	<b>(0.13)</b>	<b>(0.03)</b>	<b>(0.06)</b>	<b>(0.15)</b>	<b>0.04</b>

1. These audited consolidated financial results relate to Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) (the 'Company'), and its Subsidiaries (together the 'Group'), and Associates are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
2. The above Audited Standalone and Consolidated Financial Results were reviewed by the Audit Committee on 28th May 2026 and approved by the Board of Directors of the Company at its meeting held on 29th May 2026.
3. During the First quarter, the Company completed the incorporation of FMV Global Innovation Pte Ltd. These entities have been considered for consolidation purposes.
4. On 28th July, 2025, the Board approved the sub division of Equity shares of Rs. 10/- into 10 equity shares of Re.1 /- each by amending the capital clause of the Memorandum of Association. The shareholder's approval was obtained via postal Ballot on 30th August, 2025. Effective from the record date of 12th September, 2025, the authorized and paid-up share capital of the Company was split accordingly. Earnings Per Share (EPS) for the current and comparative periods has been proportionately adjusted and restated to ensure consistency and comparability.
5. The Government of India has consolidated 29 existing labour legislations into four Labour Codes, namely the Code on Wages, 2019; the Code on Social Security, 2020; the Industrial Relations Code, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively, the "New Labour Codes"), which have been made effective from November 21, 2025.  
Based on management's assessment, the implementation of the New Labour Codes has not resulted in any material incremental impact on the Company's gratuity obligations. Accordingly, no adjustment has been made in the financial results for the quarter. The Company is evaluating the impact of the New Labour Codes on other areas, including the contract workforce. Management does not expect any material impact. The Company continues to monitor the issuance of relevant Central and State Rules and clarifications and will recognise the impact, if any, in the financial statements.
6. During the fourth quarter, the Company has transferred its entire investment in Pellucidcare Health Innovations Pte Ltd (Formerly Known as FMV HealthCare PTE Ltd.) to its wholly-owned subsidiary, Flynncare HealthCare Innovations Private Limited. Consequent to the transfer, Pellucidcare Health Innovations Pte Ltd ceased to be a direct subsidiary of the Company and became a step down subsidiary through Flynncare HealthCare Innovations Private Limited. There was no change in the ultimate ownership or control of Pellucidcare Health Innovations Pte Ltd within the Group as a result of the transaction.

7. Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification.

8. The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company.

9. The figures for the quarter ended 31.03.2026 and 31.03.2025 are balancing figure between Audited Figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year.

10. The Statutory Auditor of the Company audited the above Standalone and Consolidated Financial Results for the Year ended 31.03.2026 and the Audit Report with an unmodified opinion was placed before the Board.

**FISCHER MEDICAL VENTURES LIMITED**

CIN: L86900AP1993PLC118162

**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH 2026**

(INR in Lakhs)

Particulars	Year ended	
	31 March 2026	31 March 2025
<b>A. CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net Profit Before Tax	-1,050.58	96.08
<b>Adjustments for non-cash and non-operating items:</b>		
Add: Depreciation and Amortization	62.74	12.72
Less : Lease Income	-3.80	-
Add: Finance Costs	200.62	13.17
Add: Provision for Bad debts	65.34	4.05
Add: Loss on Lease recognition	551.46	-
Add: Write off of PPE	0.17	-
Less: Interest Income	-152.72	-14.74
<b>Operating Profit Before Working Capital Changes</b>	<b>(326.78)</b>	<b>111.28</b>
<b>Movements in Working Capital:</b>		
(Increase) / Decrease in Trade Receivables	(428.67)	-441.62
(Increase) / Decrease in Inventories	-35.45	-6.50
(Increase) / Decrease in Other Current Assets	23.08	-302.96
(Increase) / Decrease in Other Non Current Assets	9.01	-62.31
(Increase) / Decrease in Other Current Financial Assets	38.32	-350.80
(Increase) / Decrease in Other Non Current Financial Assets	-246.31	-164.67
Increase / (Decrease) in Trade Payables	325.02	-1,164.34
Increase / (Decrease) in Other Financial Liabilities	55.69	11.27
Increase / (Decrease) in Short-Term Provisions	13.18	-
Increase / (Decrease) in Other Current Liabilities	29.71	-8.90
Increase / (Decrease) in Non-Current Provisions	10.30	-
<b>Net Working Capital Changes</b>	<b>(206.13)</b>	<b>(2,490.83)</b>
<b>Net Cash Generated from / (Used in) Operations</b>	<b>(532.91)</b>	<b>(2,379.55)</b>
Less: Taxes Paid/ Received	(39.26)	(30.79)
<b>A. NET CASH FROM / (USED IN) OPERATING ACTIVITIES</b>	<b>(572.17)</b>	<b>(2,410.34)</b>
<b>B. CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of Property, Plant & Equipment (net)	-2.93	-
Sale of Property, Plant & Equipment (net)		
Purchase of Investments in Subsidiaries / Others (net)	-1,301.67	-25,045.68
(Net investment in) / Proceeds from Fixed Deposits		-1,769.50
Repayment of loans given		3,634.8
ROU Asset	-	
Interest and Other Income Received (cash basis)		1.19
<b>B. NET CASH FROM / (USED IN) INVESTING ACTIVITIES</b>	<b>(1,304.60)</b>	<b>(23,179.20)</b>
<b>C. CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from Money received - Share Capital	165.00	3,965.10
Proceeds from Money received - Security Premium	1,149.45	23,075.47
Expenses on account of issue of shares written off		-1,506.31
Lease Liability	(622.08)	83.62
Proceeds from Long-Term Borrowings	1,296.96	-
Repayment of Lease Liabilities (Principal)		
Dividends Paid	-27.44	-
Finance costs paid		
<b>C. NET CASH FROM / (USED IN) FINANCING ACTIVITIES</b>	<b>1,961.89</b>	<b>25,617.88</b>
<b>D. NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)</b>	<b>85.13</b>	<b>28.34</b>
<b>E. Opening Cash and Cash Equivalents (31 March 2025)</b>	<b>28.71</b>	<b>0.38</b>
<b>F. Closing Cash and Cash Equivalents (31 March 2026)</b>	<b>113.84</b>	<b>28.72</b>

**Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of**

**Fischer Medical Ventures Limited**

(Formerly known as Fischer Chemic Limited)

**Opinion**

1. We have audited the accompanying consolidated annual financial results ('the Statement') of **Fischer Medical Ventures Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), for the quarter ended 31<sup>st</sup> March 2026 and for the year ended March 31<sup>st</sup> March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirements of [Regulation 33] of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate audited financial results and on the other financial information of the subsidiaries as referred to in paragraph 13 below, the Statement:
  - (i) Includes the annual financial results of its subsidiaries and associates (Refer Annexure 1)
  - (ii) And presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and
  - (iii) Gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit/loss after tax and other comprehensive income and other financial information of the Group, for the ), for the quarter ended 31<sup>st</sup> March 2026 and for the year ended March 31<sup>st</sup> March 2026

**Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in *the Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group, its associates and joint ventures, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 13 of the Other Matter section below is sufficient and appropriate to provide a basis for our opinion.

### **Responsibilities of Management and Those Charged with Governance for the Statement**

4. The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit or loss and other comprehensive income, and other financial information of the Group including its associates and joint ventures in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and its associates and joint ventures, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
5. In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors/ management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
6. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

### **Auditor's Responsibilities for the Audit of the Statement**

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;


- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
  - Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.
  - Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
  - Obtain sufficient appropriate audit evidence regarding the Consolidated Financial Results of the Company to express an opinion on the Consolidated Financial Results.
9. Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.
10. We communicate with those charged with governance of the Holding Company, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
12. We also performed procedures in accordance with SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019, issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

**Other Matters**

13. We did not audit the annual financial statements/ financial information/ financial results of its subsidiaries included in the Statement, whose financial information reflects total assets (before elimination) of Rs. 63,134.13 Lakhs as at 31<sup>st</sup> March 2026, total income (before elimination) of Rs.10,695.38 Lakhs total net profit after tax (before elimination) of Rs.625.57 , total comprehensive income/(loss) (before elimination) of Rs.624.68, for the year ended on that date, as considered in the respective audited separate annual financial result of the entities included in the group. These Annual Financial results have been audited by others auditors whose audit report(s) have been furnished to us by the management, and our opinion in so far as its relates to the amounts and disclosures included in the respect of these subsidiary is based solely on the audit report(s) of such other auditors, and the procedures performed by us as stated in paragraph 12 above.
14. Standalone financial statement of 2 company whose financial statement/financial information that reflect total assets of Rs. 1100.16 Lakhs and net assets of Rs.159.85 Lakhs as at 31 March 2026, total revenues of Rs. Nil and total net loss of subsidiaries Rs. 354.05 Lakhs for the year ended on that date, as considered in the consolidated financial statements, have not been audited. This unaudited standalone financial statement / financial information have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, and our report in terms of sub-sections (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiary is based solely on such unaudited standalone financial statement / financial information. In our opinion and according to the information and explanations given to us by the Management, this standalone financial statement / financial information is not material to the Group.

Our opinion is not modified in respect of above matter (s) with respect to our reliance on the work done by and the reports of the other auditors.

**For Bilimoria Mehta & Co**  
Chartered Accountants  
Firm Registration No.: 101490W





**Aakash Mehta**  
**Partner**  
Membership No:165824  
UDIN: 26165824RRKPOM4272  
Place of Signature: Mumbai  
Date: May 29, 2026

**Annexure 1**

<b><u>Sr no</u></b>	<b><u>Particulars</u></b>	<b><u>Stakes</u></b>	<b><u>Status</u></b>	<b><u>Auditor</u></b>
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary	Audited by SMPB & Co.
2	Time Medical Philippines (Subsidiary of Time Medical International Ventures (India) Private Limited)	75%	Step Subsidiary of Subsidiary	Mark Jayson Uy
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of Subsidiary	Unaudited
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of Subsidiary	Unaudited
5	FlynnCare Health Innovations Pvt Ltd	100%	Subsidiary of Fischer Medical Ventures Limited	Audited by SMPB & Co.
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer Medical Ventures Limited	Audited by SMPB & Co.
7	Fischer Hospitality SDN BHD	60%	Subsidiary of Fischer Medical Ventures Limited	Audited by GW and CO
8	FMV Technologies Sdn Bhd	100%	Subsidiary of Fischer Medical Ventures Limited	Unaudited
8	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited	Audited by LL Ong and Co

9	Pellucidcare Health Innovations PTE Ltd (Formerly Known as FMV HealthCare PTE Ltd.)	100%	Step Subsidiary of Subsidiary	Audited by LL Ong and Co
10	Nanyang Biologics (India) Private Limited	51%	Subsidiary of Fischer Medical Ventures Limited	Audited by SMPB & Co.
11	FMV Global Innovations PTE Ltd	100%	Subsidiary of Fischer Medical Ventures Limited	Audited by LL Ong and Co
12	PT Fischer Pariko Medical Ventures	70%	Step Subsidiary of Subsidiary	Unaudited

**Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)**

CIN : L86900AP1993PLC118162

Consolidated Balance Sheet as at March 31st, 2026

(Rs. In Lakhs)

Particulars	31st March 2026	31st March 2025
<b>Assets</b>		
<b>(1) Non-Current Assets</b>		
Property, Plant & Equipment	1,248.33	1,442.51
CWIP	293.40	111.12
ROU Asset	1,391.21	417.91
Deferred Tax Asset (Net)	159.94	38.74
Other Non Current Assets	4,811.00	2,091.34
Goodwill	671.50	527.70
<b>Financial Assets</b>	-	
(i) Investments	12,321.06	694.55
	-	
(ii) Other Financial asset	4,929.84	3,884.54
<b>Total Non-Current Assets</b>	<b>25,826.29</b>	<b>9,208.39</b>
<b>(2) Current assets</b>	-	
(a) Inventories	1,266.32	916.37
(b) Financial assets	-	
(i) Trade receivables	28,879.80	7,606.63
(ii) Cash and cash equivalents	1,188.94	10,426.28
(iii) Bank balances other than cash and cash equivalents	1,315.64	15,067.18
(iv) Other Current Financial Asset	265.25	50.94
(v) Others	-	-
(b) Other Current Asset	-	
-Loans and Advances	-	
-Other Current Financial Asset	0.49	
(c) Current Tax Asset (Net)	9.15	
(d) Other Current Assets	8,448.53	2,461.25
<b>Total Current Assets</b>	<b>41,374.13</b>	<b>36,528.65</b>
<b>Total Assets</b>	<b>67,200.42</b>	<b>45,737.03</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	6,545.15	6,380.15
(b) Other Equity	-	
Reserve & Surplus	29,203.16	24,369.77
	-	
Non Controlling Interest	178.02	34.15
Foreign Currency Translation Reserve (FCTR)	148.24	-21.41
Money received against share warrants	2,583.95	3,022.10
	-	
<b>Total Equity</b>	<b>38,658.53</b>	<b>33,784.77</b>
<b>Liabilities</b>		
<b>(1) Non-Current Liabilities</b>		
(a) Deferred Tax Liability	(44.92)	39.27
(b) Financial Liabilities	-	
(i) Lease Liabilities	2,659.41	1,773.23
(ii) Borrowings	26.09	26.25
(iii) Other Financial Liabilities	-	-
(iv) Provisions	98.75	8.51
<b>Total Non-Current Liabilities</b>	<b>2,739.33</b>	<b>1,847.26</b>
<b>(2) Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	7,209.92	6,013.86
(i) Lease Liabilities	812.11	723.88
(ii) Trade payables	-	-
total outstanding dues of micro enterprises and small enterprises	1,015.87	1,472.64
total outstanding dues of creditors other than micro enterprises and small	9,244.51	592.84
(iii) Other Financial liabilities	116.94	47.25
(b) Short Term Provisions	6,061.57	-
(b) Other Current Liabilities	1,341.95	1,174.62
(c) Current Tax	-	-
(d) Provisions	(0.43)	58.80
(e) Current Tax Liability (Net)	-	21.11
<b>Total Current Liabilities</b>	<b>25,802.43</b>	<b>10,105.00</b>
<b>Total Equity and Liabilities</b>	<b>67,200.29</b>	<b>45,737.03</b>

## Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900AP1993PLC118162

## CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED March 31, 2026

(Amount in lakhs)

Particulars	Quarter ended			Year ended	Year ended
	March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
	Audited	Unaudited	Audited	Audited	Audited
I) Revenue From Operations	9,773.04	10,109.52	4,917.42	30,857.56	11,069.87
II) Other Income	127.78	108.81	14.87	1,231.37	149.20
III) Total Income (I+II)	<b>9,900.83</b>	<b>10,218.32</b>	<b>4,932.28</b>	<b>32,088.93</b>	<b>11,219.07</b>
<b>Expenses :</b>					
Cost of Material Consumed	6,209.35	-	-	6,224.23	-
Purchase of Goods	690.33	5,781.06	3,472.30	8,349.15	9,528.18
Changes in inventories of finished goods, by-products and work in progress	(53.55)	(891.88)	458.75	(315.59)	(369.22)
Direct Expenses	256.43	127.36	-	5,301.23	-
Employee Benefit expenses	402.13	416.77	93.58	1,509.42	258.13
Finance Cost	360.83	63.71	22.63	583.40	46.68
Depreciation and Amortization Expenses	92.57	77.01	51.03	297.93	163.28
Other Expenses	2,168.05	2,519.71	642.46	5,480.78	1,321.10
<b>Total Expenses (IV)</b>	<b>10,126.13</b>	<b>8,093.74</b>	<b>4,740.76</b>	<b>27,430.55</b>	<b>10,948.15</b>
V) Profit (Loss) Before exceptional and tax (III-IV)	<b>(225.30)</b>	<b>2,124.58</b>	<b>191.52</b>	<b>4,658.38</b>	<b>270.93</b>
VI) Exceptional Items		-	-	-	-
<b>Profit before tax (V+VI)</b>	<b>(225.30)</b>	<b>2,124.58</b>	<b>191.52</b>	<b>4,658.38</b>	<b>270.93</b>
VII) Tax Expenses					
i) Current Tax	(842.87)	(172.25)	(53.95)	(1,731.88)	(107.95)
ii) Deferred Tax	288.77	(23.12)	9.35	129.08	11.87
iii) Tax pertaining to previous year	-	-	(5.40)	-	(5.40)
iv) Minimum Alternate Tax	68.55			68.55	
VIII) Profit (Loss) from Continuing Operations (VI+VII)	<b>(710.86)</b>	<b>1,929.21</b>	<b>141.52</b>	<b>3,124.14</b>	<b>169.45</b>
IX) Profit (Loss) from Discontinuing Operations		-	-	-	-
X) Tax Expenses for Discontinuing Operations		-	-	-	-
XI) Profit (Loss) from Discontinuing Operations (After Tax) (IX+X)		-	-	-	-
IX) Profit (Loss) for the period (XI+XII)	<b>(710.86)</b>	<b>1,929.21</b>	<b>141.52</b>	<b>3,124.14</b>	<b>169.45</b>
XII) Other Comprehensive income;					
(i) Items that will not be reclassified to profit or loss			(0.78)	5.43	(0.78)
B (i) Items that will be reclassified to profit or loss			-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss			-	-	-
XIII) Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (VIII+XI+XII)	<b>(710.86)</b>	<b>1,929.21</b>	<b>140.76</b>	<b>3,118.70</b>	<b>168.67</b>
XIV) Share of Profit/Loss from Associate					
- The Therapy Platform Pte Ltd	(3.25)	(5.08)	(1.53)	(3.87)	(13.29)
- Bluesim tech pte ltd FS	2.17	(0.66)	(8.79)	(18.32)	(35.36)
XVI) Profit for the Period (XIII+XIV)	<b>(709.78)</b>	<b>1,923.47</b>	<b>130.44</b>	<b>3,096.51</b>	<b>120.02</b>
Paid up Equity Share Capital (Face Value Re.1/-)	<b>6,485.15</b>	<b>6,485.15</b>	<b>6,380.15</b>	<b>6,485.15</b>	<b>6,380.15</b>
XVII) Earnings per Equity Shares					
1) Basic	<b>(0.11)</b>	<b>0.30</b>	<b>0.02</b>	<b>0.48</b>	<b>0.02</b>
2) Diluted	<b>(0.10)</b>	<b>0.29</b>	<b>0.01</b>	<b>0.45</b>	<b>0.01</b>

1. These audited consolidated financial results relate to Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) (the 'Company'), and its Subsidiaries (together the 'Group'), and Associates are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
2. The above Audited Standalone and Consolidated Financial Results were reviewed by the Audit Committee on 28th May 2026 and approved by the Board of Directors of the Company at its meeting held on 29th May 2026.
3. During the First quarter, the Company completed the incorporation of FMV Global Innovation Pte Ltd. These entities have been considered for consolidation purposes.
4. On 28th July, 2025, the Board approved the sub division of Equity shares of Rs. 10/- into 10 equity shares of Re.1 /- each by amending the capital clause of the Memorandum of Association. The shareholder's approval was obtained via postal Ballot on 30th August, 2025. Effective from the record date of 12th September, 2025, the authorized and paid-up share capital of the Company was split accordingly. Earnings Per Share (EPS) for the current and comparative periods has been proportionately adjusted and restated to ensure consistency and comparability.
5. The Government of India has consolidated 29 existing labour legislations into four Labour Codes, namely the Code on Wages, 2019; the Code on Social Security, 2020; the Industrial Relations Code, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively, the "New Labour Codes"), which have been made effective from November 21, 2025.  
Based on management's assessment, the implementation of the New Labour Codes has not resulted in any material incremental impact on the Company's gratuity obligations. Accordingly, no adjustment has been made in the financial results for the quarter. The Company is evaluating the impact of the New Labour Codes on other areas, including the contract workforce. Management does not expect any material impact. The Company continues to monitor the issuance of relevant Central and State Rules and clarifications and will recognise the impact, if any, in the financial statements.
6. During the fourth quarter, the Company has transferred its entire investment in Pellucidcare Health Innovations Pte Ltd (Formerly Known as FMV HealthCare PTE Ltd.) to its wholly-owned subsidiary, Flynncare HealthCare Innovations Private Limited. Consequent to the transfer, Pellucidcare Health Innovations Pte Ltd ceased to be a direct subsidiary of the Company and became a step down subsidiary through Flynncare HealthCare Innovations Private Limited. There was no change in the ultimate ownership or control of Pellucidcare Health Innovations Pte Ltd within the Group as a result of the transaction.

7. Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification.

8. The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company.

9. The figures for the quarter ended 31.03.2026 and 31.03.2025 are balancing figure between Audited Figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year.

10. The Statutory Auditor of the Company audited the above Standalone and Consolidated Financial Results for the Year ended 31.03.2026 and the Audit Report with an unmodified opinion was placed before the Board.

**Annexure -2**

**Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015**

S No.	Particulars	Details
1	Name of Audit firm	M/S S. Ramanand Aiyer & Co (FRN: 000990N), Chartered Accountants
2	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Internal Auditors for FY 2026-27
3	Date of appointment/cessation (as applicable)	29th May 2026
4	Term of Appointment	M/S. Ramanand Aiyer & Co., Chartered Accountants, New Delhi, appointed by the Board of Directors of the Company, as an Internal Auditor to conduct the Internal audit of the records of the Company for the financial year 2026-27.
5	Brief Profile	<b>M/S S. Ramanand Aiyer &amp; Co. (SRA)</b> is a chartered accountancy firm founded in 1950 in New Delhi. Built on a legacy of professional ethics, integrity, and service excellence, SRA has evolved over 75+ years to deliver quality, innovative, and client-focused solutions. The firm expanded through strategic partnerships to establish a PAN-India presence with offices in New Delhi, Mumbai, Indore, Bengaluru, Chennai, Kolkata, Hyderabad, and Ernakulam. Supported by 16 partners, 10+ chartered accountants and other professionals, and over 75 article assistants, SRA serves a diverse client base of corporates, PSUs, banks, NGOs, educational institutions, start-ups, and HNIs across sectors such as manufacturing, infrastructure, financial services, healthcare, hospitality, and banking. With robust systems and deep expertise in Indian laws and global best practices, SRA continues to act as a trusted advisor and growth partner to businesses nationwide.
6	Disclosure of relationship between directors	Not applicable